Argenx Impresses This Morning

By Susan Ramirez • Wednesday, May 17 12:23 • Permanent Link

Large-cap Health Care company Argenx SE has logged a 2.3% change today on a trading volume of 514,000. The average volume for the stock is 234,591.

Argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Based in Amsterdam, Netherlands the company has 843 full time employees and a market cap of $23,095,832,576.

The company is now trading -10.39% away from its average analyst target price of $462.9 per share. The 20 analysts following the stock have set target prices ranging from $374.0 to $544.0, and on average give argenx SE a rating of buy.

Over the last year, ARGX shares have gone up 33.1%, which represents a difference of 28.0% when compared to the S&P 500. The stock's 52 week high is $417.0 per share whereas its 52 week low is $302.24.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.